VistaGen Therapeutics, Inc. (VTGN) Report Analysis
Corporate Events
VistaGen Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
2022-06-23 00:00:00
VistaGen Therapeutics, Inc. filed its 10-K on Jun 23, 2022 for the period ending Mar 31, 2022. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can continue as a going concern.
VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer
2022-06-22 20:55:00
On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the “Company”) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company’s President and Chief Scientific Officer.
Vistagen Therapeutics, Inc. Announces Completion of Palisade-1 Phase 3 Clinical Study of Ph94b for the Acute Treatment of Social Anxiety Disorder
2022-06-22 12:30:00
VistaGen Therapeutics, Inc. announced that the last patient has completed the study protocol in its PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder (SAD). VistaGen’s PALISADE-1 Phase 3 clinical trial is a U.S. multi-center, randomized, double-blind, placebo-controlled, parallel design, clinical study in adults diagnosed with SAD. The study is designed to evaluate the efficacy, safety, and tolerability of the acute administration of PH94B to relieve symptoms of anxiety in adult patients living with SAD during a simulated public speaking challenge conducted in a clinical setting, measured using the Subjective Units of Distress Scale (SUDS). Topline results from VistaGen’s PALISADE-1 Phase 3 clinical study are anticipated in mid-2022, consistent with the Company’s prior guidance. VistaGen is also evaluating PH94B for SAD in a second Phase 3 clinical trial, PALISADE-2, a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed as a replicate of PALISADE-1 to evaluate the efficacy, safety, and tolerability of PH94B for the acute treatment of anxiety in adults with SAD. Topline results from PALISADE-2 are anticipated in late-2022. VistaGen’s PALISADE Phase 3 Program in social anxiety disorder (SAD) is designed to further demonstrate the potential of PH94B as a fast-acting, acute treatment of anxiety in adults with SAD. The Company’s PALISADE-1 and PALISADE-2 Phase 3 clinical trials are replicate U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trials designed to evaluate the efficacy, safety, and tolerability of PH94B for the acute treatment of anxiety in adults with SAD. If the Company’s PALISADE Phase 3 Program is successful, then VistaGen plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) to approve the use of PH94B for the acute treatment of anxiety in adults with SAD. The FDA has granted Fast Track designation for the development of PH94B for SAD. VistaGen’s PH94B is a first-in-class, odorless, tasteless, rapid-onset (approximately 15 minutes) investigational pherine nasal spray with a novel mechanism of action (MOA) that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic autonomic nervous system. Based on positive Phase 2 data in social anxiety disorder (SAD) patients, VistaGen is currently evaluating PH94B in two Phase 3 clinical studies in the U.S., PALISADE-1 and PALISADE-2, for the acute treatment of anxiety in adults with SAD. Designed for intranasal administration in low microgram doses, the proposed novel MOA of PH94B is fundamentally differentiated from all currently approved anti-anxiety medications, including benzodiazepines. VistaGen’s proposed MOA for PH94B does not involve either direct activation of GABA-A receptors or binding to neuronal receptors in the central nervous system (CNS). Rather, PH94B’s proposed MOA involves binding to receptors in peripheral chemosensory neurons in the nasal passages to regulate the olfactory-amygdala fear and anxiety neural circuits. Both clinical and preclinical data suggest that PH94B has the potential to achieve rapid-onset anti-anxiety effects without systemic uptake or transport into the brain, reducing the risk of benzodiazepine-like side effects and other safety concerns. VistaGen is conducting a Phase 2A clinical trial to evaluate the potential use of PH94B to treat adjustment disorder with anxiety and is considering the evaluation of PH94B for potential use in the treatment of other anxiety-related disorders, including procedural anxiety, post-traumatic stress disorder (PTSD), postpartum anxiety, and panic disorder.
VistaGen Therapeutics, Inc., 2022 Earnings Call, Jun 23, 2022
2022-06-17 12:30:00
VistaGen Therapeutics, Inc., 2022 Earnings Call, Jun 23, 2022
VistaGen Therapeutics, Inc. to Report Fiscal Year 2022 Results on Jun 23, 2022
2022-06-17 12:30:00
VistaGen Therapeutics, Inc. announced that they will report fiscal year 2022 results on Jun 23, 2022
VistaGen Therapeutics, Inc. Presents at American Society of Clinical Psychopharmacology 2022 Annual Meeting, May-31-2022
2022-05-21 02:32:00
VistaGen Therapeutics, Inc. Presents at American Society of Clinical Psychopharmacology 2022 Annual Meeting, May-31-2022 . Venue: Scottsdale, Ariz, Scarsdale, United States.
VistaGen Therapeutics, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-07-2022 03:00 PM
2022-05-21 02:32:00
VistaGen Therapeutics, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-07-2022 03:00 PM. Venue: Loews Chicago Hotel, Chicago, Illinois, United States. Speakers: Shawn K. Singh, CEO & Director.
VistaGen Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM
2022-05-21 02:32:00
VistaGen Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 10:00 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Shawn K. Singh, CEO & Director.
VistaGen Announces Key Regulatory Update on Ph94b for the Acute Treatment of Social Anxiety Disorder
2022-05-05 12:30:00
VistaGen Therapeutics, Inc. announced a key regulatory update on its PALISADE Phase 3 Program for PH94B for the acute treatment of anxiety in adults with social anxiety disorder (SAD). The U.S. Food and Drug Administration (FDA) recently indicated the following regarding VistaGen’s late-stage development of PH94B for the acute treatment of SAD: Nonclinical and clinical data in studies completed to date provide no signal of abuse potential; Receptor binding data do not show that PH94B has affinity for abuse-related sites, such as dopamine, opiate or GABA; Intravenous administration of PH94B to animals provides no overt behavioral responses; No additional nonclinical studies are needed to evaluate the abuse potential of PH94B; and While the need for a human abuse potential (HAP) study with PH94B may be revisited by the FDA upon completion of current and planned clinical trials, because studies completed to date provide no signal of abuse potential, at this time, conducting a HAP study of PH94B is not necessary. VistaGen’s PH94B is a first-in-class, odorless, tasteless rapid-onset (10-15 minutes) investigational pherine nasal spray with a novel mechanism of action (MOA) that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic autonomic nervous system. Based on positive Phase 2 data in social anxiety disorder (SAD) patients, VistaGen is currently evaluating PH94B in two Phase 3 clinical studies in the U.S., PALISADE-1 and PALISADE-2, and a long-term safety study, for the acute treatment of anxiety in adults with SAD. Designed for intranasal administration in low microgram doses, the innovative MOA of PH94B is fundamentally differentiated from all current anti-anxiety medications, including benzodiazepines. PH94B’s proposed MOA does not involve either direct activation of GABA-A receptors [2]or binding to neuronal receptors [3] in the CNS. Rather, PH94B’s proposed MOA involves binding to peripheral chemosensory neurons in the nasal passages to modulate the olfactory-amygdala fear and anxiety neural circuits. Both clinical and preclinical data suggest that PH94B has the potential to achieve rapid-onset anti-anxiety effects without systemic uptake or transport into the brain, reducing the risk of benzodiazepine-like side effects and other safety concerns. In addition to SAD, for which the FDA has granted Fast Track designation, PH94B has potential in adjustment disorder with anxiety, procedural anxiety, PTSD, postpartum anxiety and panic disorder.
VistaGen Therapeutics, Inc. Appoints Reid Adler as Chief Legal Officer
2022-05-02 12:00:00
VistaGen Therapeutics, Inc. announced the appointment of Reid Adler as its Chief Legal Officer. Adler will oversee company's legal affairs and provide strategic guidance to its Executive Team and Board of Directors. With a legal career spanning more than three decades, Adler joins the company from the law firm Capital Technology Law Group, where he served as the legal counsel for several technology and life science businesses and not-for-profits, over the past decade. Adler has been at the forefront of strategic planning, developing programs and policies for various types of organizations, providing governance advice to senior management, negotiating complex technology transactions and the strategic management of intellectual property assets. His career includes experience as a senior partner at two international law firms, Morrison & Foerster and Morgan Lewis, as well as general counsel to the pioneering J. Craig Venter Institute for genomics. He has also consulted with several multinational pharmaceutical companies on product exclusivity and for the Coalition for Epidemic Preparedness Innovations on legal and business development aspects of vaccines. Adler was the founding director of the National Institutes of Health (NIH) Office of Technology Transfer, where he built a team of over 40 people to evaluate the translation of research projects into health care products. He played a key role at the NIH in developing policies and model agreements, research integrity guidelines and the Uniform Biological Material Transfer Agreement, currently used by hundreds of organizations worldwide.
American Society Of Clinical Psychopharmacology Inc, American Society of Clinical Psychopharmacology 2022 Annual Meeting, May 31, 2022 through Jun 03, 2022
2022-05-02 11:00:00
American Society Of Clinical Psychopharmacology Inc, American Society of Clinical Psychopharmacology 2022 Annual Meeting, May 31, 2022 through Jun 03, 2022. Venue: Scottsdale, Ariz, Scarsdale, United States.
VistaGen Therapeutics, Inc. to Present Preclinical Data on Lead Candidate PH94B At Upcoming Scientific Congresses
2022-04-22 10:10:00
VistaGen Therapeutics, Inc. announced that researchers will present preclinical data supporting the differentiated mechanism of action (MOA) for VistaGen’s lead product candidate, PH94B, at two upcoming major scientific congresses. VistaGen is currently evaluating PH94B in multiple Phase 3 trials for the acute treatment of anxiety in adults with social anxiety disorder (SAD). Late last year, VistaGen released preclinical data that further support that the proposed MOA of PH94B involves binding to receptors of peripheral neurons in the nasal passages, rather than neuronal receptors in the CNS. These data suggest that anxiolytic activity can be achieved without systemic exposure or transport into the brain, resulting in a lower risk for side effects. VistaGen’s PH94B is a first-in-class, rapid-onset (approximately 15 minutes) pherine nasal spray being evaluated for the acute treatment of SAD in adults. Pherines are odorless, synthetic neuroactive steroids that bind to distinct receptors on chemosensory cells in the nasal passages and can impact the limbic amygdala without systemic uptake. Designed to be administered intranasally at microgram doses, the unique potential MOA of PH94B is fundamentally differentiated from all current anti-anxiety medications, including benzodiazepines. PH94B’s proposed MOA does not involve either direct activation of GABA-A receptors or binding to neuronal receptors in the CNS. Rather, PH94B’s proposed MOA involves binding to peripheral neurons in the nasal passages, with very limited systemic exposure. Taken together, these data suggest that PH94B has the potential to achieve rapid-onset anti-anxiety effects without systemic uptake or transport into the brain, reducing the risk of benzodiazepine-like side effects and other safety concerns. VistaGen is currently evaluating PH94B in two Phase 3 clinical studies in the U.S., PALISADE-1 and PALISADE-2, and a long-term safety study, for the acute treatment of anxiety in adults with SAD. The FDA has granted Fast Track designation for the development of PH94B as a potential treatment for SAD.
VistaGen Therapeutics, Inc. and AffaMed Therapeutics Complete Key Regulatory Submissions for Palisade Global Phase 3 Clinical Trial for PH94B
2022-04-12 11:00:00
VistaGen Therapeutics, Inc. and AffaMed Therapeutics announced they have completed regulatory preparations to initiate PALISADE Global, a Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of VistaGen’s PH94B for the acute treatment of anxiety in adults with social anxiety disorder, in the U.S. and China. The primary purpose of PALISADE Global, the design of which is based on VistaGen’s ongoing PALISADE-1 and PALISADE-2 Phase 3 clinical studies of PH94B in the U.S., is to support potential commercialization of PH94B in China and other markets outside of the U.S. VistaGen’s recent submission of the PALISADE Global study protocol to the U.S. Food and Drug Administration under its existing PH94B Investigational New Drug application in SAD and AffaMed’s recent receipt of regulatory clearance of its Clinical Trial Application from the National Medical Products Administration in China have cleared the way for initiation of PALISADE Global in the U.S. and China during the second half of 2022. The companies also anticipate initiating this Phase 3 study in Canada, Mexico, and South Korea. PH94B is an odorless, fast-acting neuroactive pherine nasal spray with a unique potential mechanism of action for the acute treatment of anxiety in adults with SAD. PH94B works differently than all therapies currently approved for the treatment of SAD by either the FDA or the NMPA. In June 2020, VistaGen Therapeutics entered into a strategic licensing and collaboration agreement with AffaMed Therapeutics for the clinical development and commercialization of PH94B in China, South Korea, and Southeast Asia. To date, health authorities in the U.S. and China have not approved any medications for acute treatment of anxiety in adults with SAD. SAD is commonly treated in the U.S. with certain antidepressants approved by the FDA, which have a slow onset and limited therapeutic benefits. Benzodiazepines, which are not FDA-approved for the treatment of SAD, are prescribed for off-label use. Both antidepressants and benzodiazepines have known side effects and safety concerns that may make them unattractive to many individuals affected by SAD.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
VistaGen Therapeutics, Inc. Announces Clinical Trials Update
2022-02-10 21:20:00
VistaGen Therapeutics, Inc. continued consistent progress across its nasal spray, pherine-based platform and novel oral NMDA (N-methyl-D-aspartate) receptor program. The Company’s ongoing randomized, multi-center, double-blind, placebo-controlled PALISADE-1 and PALISADE-2 Phase 3 clinical trials in the U.S. are designed to evaluate the efficacy, safety, and tolerability of PH94B for the acute treatment of anxiety in adults with SAD. PH94B is an odorless, rapid-onset pherine nasal spray with a unique potential mechanism of action (MOA) for the acute treatment of anxiety in adults with SAD, designed to work differently than all therapies approved by the U.S. Food and Drug Administration (FDA) for SAD. Both studies are structured in a manner substantially similar to the public speaking component of a statistically significant peer-reviewed published Phase 2 study of PH94B in which researchers observed a rapid reduction in anxiety in individuals (within 15 minutes) in response to a public speaking challenge (p=0.002). The Company anticipates that topline data will be available in mid-2022 and in the second half of 2022 for PALISADE-1 and PALISADE-2, respectively. The full PALISADE Phase 3 program for PH94B in SAD consists of the two Phase 3 trials, PALISADE-1 and PALISADE-2, as well as the PALISADE Long-term Safety Study and certain small studies designed to support the filing of a U.S. New Drug Application (NDA) to the FDA should the program be successful. During the third quarter, the Company launched the first study in a series of exploratory clinical trials to evaluate PH94B’s potential in several anxiety disorders beyond SAD. The initial study in the exploratory program is a Phase 2A clinical trial designed to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of adults with adjustment disorder with anxiety (AjDA). Topline data from this AjDA trial is expected in the second half of 2022. The Company expects to launch additional exploratory clinical studies of PH94B later this year. The Company reported new preclinical data that support the MOA of PH94B binding to receptors of peripheral neurons in the nasal passages, rather than to neuronal receptors in the CNS, without measurable systemic exposure. These data are important as they further support previous data showing that PH94B does not directly activate GABA-A receptors, which is in distinct contrast to the MOA of benzodiazepines, and are part of the growing body of evidence suggesting that PH94B has the potential to achieve anti-anxiety effects without requiring systemic uptake or causing benzodiazepine-like side effects and safety concerns. PH10 Nasal Spray development continues for multiple depression disorders – PH10 has potential as a novel therapeutic for treatment of multiple depression disorders. Following a positive exploratory Phase 2A study of PH10 in major depressive disorder (MDD), the Company is preparing to initiate a randomized, multi-center, double-blind, placebo-controlled Phase 2B clinical study of PH10 as a potential rapid-onset stand-alone treatment in MDD in the second half of 2022. AV-101 + probenecid Phase 1B trial initiated – Following positive preclinical data showing that the combination of AV-101 and probenecid substantially increased the brain concentration of AV-101's active metabolite, thereby demonstrating potential to reduce, rather than block, NMDA receptor signaling, VistaGen initiated a Phase 1B drug-drug interaction study of the combination at the end of the fiscal third quarter. The FDA has granted Fast Track designation for development of AV-101 as a potential adjunctive treatment for MDD and as a non-opioid treatment for neuropathic pain. The Company believes AV-101 in combination with probenecid also may have potential as a treatment for levodopa-induced dyskinesia associated with Parkinson’s disease therapy, suicidal ideation, epilepsy, and other neurological disorders involving the NMDA receptor.
VistaGen Therapeutics, Inc. to Report Q3, 2022 Results on Feb 10, 2022
2022-02-07 13:00:00
VistaGen Therapeutics, Inc. announced that they will report Q3, 2022 results on Feb 10, 2022
VistaGen Therapeutics, Inc., Q3 2022 Earnings Call, Feb 10, 2022
2022-02-07 13:00:00
VistaGen Therapeutics, Inc., Q3 2022 Earnings Call, Feb 10, 2022
William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022
2022-01-25 11:00:00
William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.
VistaGen Therapeutics, Inc., Q2 2022 Earnings Call, Nov 10, 2021
2021-11-04 12:00:00
VistaGen Therapeutics, Inc., Q2 2022 Earnings Call, Nov 10, 2021
VistaGen Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM
2021-10-19 15:02:00
VistaGen Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: Shawn K. Singh, CEO & Director.
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
2021-10-14 12:00:00
VistaGen Therapeutics, Inc. announced the initiation of a Phase 2A clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with Adjustment Disorder with Anxiety (AjDA). In parallel with advancing its ongoing PALISADE Phase 3 clinical program for PH94B in the acute treatment of anxiety in adults with Social Anxiety Disorder (SAD), the Company plans to explore PH94B’s potential in additional anxiety disorders through a series of small Phase 2A trials, the first of which is in AjDA. PH94B is an investigational pherine nasal spray with a unique potential mechanism of action designed to achieve rapid-onset anti-anxiety effects without requiring systemic uptake or causing benzodiazepine-like side effects and safety concerns. The exploratory Phase 2A clinical trial of PH94B in AjDA is a randomized, double-blind, placebo-controlled study with an enrollment target of approximately 40 adults at clinical sites in the Boston and New York City metro areas. Dr. Michael Liebowitz, a Columbia University psychiatrist, former director and founder of the Anxiety Disorders Clinic at the New York State Psychiatric Institute, and director of the Medical Research Network in New York City is serving as Principal Investigator of the trial. The study’s primary outcome measure is the change from baseline in anxiety level as measured by the Hamilton Anxiety Rating Scale (HAM-A). Almost everyone experiences significant life events, changes, or stressors from time to time, and while some individuals adjust to such changes within a few months, others cannot and may experience adjustment disorder. Adjustment Disorder with Anxiety (AjDA) is the development of emotional or behavioral symptoms considered excessive or disproportionate in response to a sudden change, stressful event or circumstance, or other identifiable anxiety-provoking stressor, such as loss of work, divorce or a health setback, significantly impairing a person’s social, occupational and/or other important area(s) of functioning. About PH94B PH94B is a first-in-class, odorless, rapid-onset (approximately 15 minutes) pherine nasal spray with the potential to be the first FDA-approved, fast-acting, on-demand acute treatment for millions of Americans who suffer from Social Anxiety Disorder (SAD), with additional therapeutic potential in Adjustment Disorder with Anxiety (AjDA), Postpartum Anxiety, Procedural Anxiety, Post-traumatic Stress Disorder, Panic Disorder and Generalized Anxiety Disorder. Designed to be administered intranasally at microgram doses, the proposed mechanism of action (MOA) of PH94B is fundamentally differentiated from that of all current anti-anxiety medications, including benzodiazepines. PH94B’s proposed MOA does not involve either direct activation of GABA-A receptors or binding to neuronal receptors in the CNS. Rather, PH94B’s proposed MOA involves binding to peripheral neurons in the nasal passages, thereby limiting transport of molecules to the circulatory system and minimizing potential systemic exposure, suggesting that PH94B has the potential to achieve rapid-onset anti-anxiety effects without requiring systemic uptake or causing benzodiazepine-like side effects and safety concerns.
Vistagen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B’s Potential Anti-Anxiety Activity Via Peripheral Nasal Neurons Without Entry into the Brain
2021-10-05 21:23:00
VistaGen Therapeutics announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats demonstrating that a single intranasal administration of radiolabeled carbon-14 PH94B was largely confined to the nasal passages and minimal or undetectable in most other tissues, including the CNS. No appreciable activity was observed in the brain. These data further support the proposed mechanism of action of PH94B involving binding to receptors of peripheral neurons in the nasal passages, not to neuronal receptors in the CNS, and thereby limiting transport of molecules to the circulatory system and minimizing potential systemic exposure.
VistaGen Therapeutics, Inc. has filed a Shelf Registration in the amount of $30.975 million.
2021-09-24 00:00:00
VistaGen Therapeutics, Inc. has filed a Shelf Registration in the amount of $30.975 million. Security Name: Common Stock Securities Offered: 10,500,000 Transaction Features: ESOP Related Offering
VistaGen Therapeutics, Inc.(NasdaqCM:VTGN) added to S&P Global BMI Index
2021-09-20 00:00:00
VistaGen Therapeutics, Inc.(NasdaqCM:VTGN) added to S&P Global BMI Index
VistaGen Therapeutics, Inc.(NasdaqCM:VTGN) added to S&P Biotechnology Select Industry Index
2021-09-20 00:00:00
VistaGen Therapeutics, Inc.(NasdaqCM:VTGN) added to S&P Biotechnology Select Industry Index
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2
2021-09-13 10:00:00
VistaGen Therapeutics, Inc. announced the initiation of PALISADE-2, the second U.S. Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of PH94B for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”). PH94B is designed to be an odorless, rapid-onset pherine nasal spray with a unique potential mechanism of action for the acute treatment of anxiety in adults with SAD, working differently than all therapies approved by the U.S. Food and Drug Administration (the “FDA”) indicated for SAD. PALISADE-2 is a randomized, multi-center, double-blind, placebo-controlled clinical trial that is a replicate of VistaGen’s ongoing PALISADE-1 trial of PH94B for the acute treatment of anxiety in adults with SAD. Both studies are designed in a manner that is substantially similar to the public speaking component of a peer-reviewed published Phase 2 study of PH94B for the acute treatment of anxiety in adults with SAD. In that Phase 2 study, PH94B was observed to have rapid reduction in anxiety (within 15 minutes) in response to a public speaking challenge (p=0.002). PALISADE-2 will be conducted across approximately 15 clinical sites in the United States, with a target of approximately 208 patients. Dr. Michael Liebowitz, a Columbia University psychiatrist, former director and founder of the Anxiety Disorders Clinic at the New York State Psychiatric Institute, director of the Medical Research Network in New York City, and creator of the Liebowitz Social Anxiety Scale, is serving as principal investigator of the trial. Topline results from PALISADE-1 and PALISADE-2 are anticipated in mid-2022 and in the second half of 2022, respectively.
VistaGen Therapeutics, Inc. Presents at Maxim Group and M-Vest, Advances in Mental Health Virtual Conference, Sep-22-2021 02:00 PM
2021-09-10 13:37:00
VistaGen Therapeutics, Inc. Presents at Maxim Group and M-Vest, Advances in Mental Health Virtual Conference, Sep-22-2021 02:00 PM. Speakers: Shawn K. Singh, CEO & Director.
M Vest LLC, Maxim Group, LLC, Maxim Group and M-Vest, Advances in Mental Health Virtual Conference, Sep 22, 2021
2021-09-10 12:22:00
M Vest LLC, Maxim Group, LLC, Maxim Group and M-Vest, Advances in Mental Health Virtual Conference, Sep 22, 2021.
VistaGen Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 03:10 PM
2021-08-26 17:20:00
VistaGen Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 03:10 PM. Speakers: Shawn K. Singh, CEO & Director.
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021
2021-08-10 13:03:00
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.
VistaGen Therapeutics, Inc. to Report Q1, 2022 Results on Aug 12, 2021
2021-08-10 00:00:00
VistaGen Therapeutics, Inc. announced that they will report Q1, 2022 results on Aug 12, 2021
VistaGen Therapeutics, Inc., Q1 2022 Earnings Call, Aug 12, 2021
2021-08-09 20:05:00
VistaGen Therapeutics, Inc., Q1 2022 Earnings Call, Aug 12, 2021
VistaGen Therapeutics, Inc. - Shareholder/Analyst Call
2021-07-29 21:13:00
Annual Meeting of Stockholders
VistaGen Therapeutics, Inc., Annual General Meeting, Sep 17, 2021
2021-07-29 21:13:00
VistaGen Therapeutics, Inc., Annual General Meeting, Sep 17, 2021, at 10:00 Pacific Standard Time. Agenda: To elect seven directors to the Board of Directors, each to serve until 2022 Annual Meeting of Stockholders, or until her or his respective successor is elected and qualified; to approve an amendment and restatement of the company's 2019 Omnibus Equity Incentive Plan (the Amended 2019 Plan), which Amended 2019 Plan makes certain changes to the company's 2019 Omnibus Equity Incentive Plan, including increasing the number of shares of the common stock authorized for issuance thereunder from 7.5 million shares to 18 million shares; to ratify the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year ending March 31, 2022; and to vote upon such other matters, if any, as may properly come before the Annual Meeting or any adjournment or postponement of the Meeting.
VistaGen Therapeutics, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 04:30 PM
2021-07-22 20:49:00
VistaGen Therapeutics, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 04:30 PM. Speakers: Mark Flather, Vice President, Investor Relations, Mark Adrian McPartland, Vice President of Corporate Development, Shawn K. Singh, CEO & Director.
Vistagen Therapeutics Announces Appointment of Maggie FitzPatrick to Its Board of Directors
2021-07-22 12:00:00
VistaGen Therapeutics, Inc. announced the appointment of Maggie FitzPatrick to its Board of Directors (“Board”), replacing Dr. Brian J. Underdown who recently retired from the Board. Ms. FitzPatrick is a globally recognized corporate affairs executive who has been honored with several prestigious awards, including the Washington Business Journal’s C-Suite Executive of the Year Class (2019), PR Week’s Top 50 Most Powerful People in PR (2015) and PR Week’s Hall of Femme (2019). Recently, she served as a member of the Exelon Corporation executive committee. At Exelon, she led communications, customer engagement, digital and crisis reputation management and philanthropy for the Fortune 100 Company.
Vistagen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors
2021-07-07 12:30:00
VistaGen Therapeutics, Inc. announced the appointment of Mary L. Rotunno, J.D. to its Board of Directors. Ms. Rotunno is currently General Counsel and Member of the Executive Leadership Team at El Camino Health, a $1 billion revenue health care system. She is also Board Chair and a member of Audit, Executive/Governance and Nominations Committees for health care provider, Momentum for Health, in Silicon Valley.
VistaGen Therapeutics, Inc. Presents at William Blair Biotech Focus Conference 2021, Jul-15-2021 12:00 PM
2021-07-02 14:50:00
VistaGen Therapeutics, Inc. Presents at William Blair Biotech Focus Conference 2021, Jul-15-2021 12:00 PM. Speakers: Shawn K. Singh, CEO & Director.
Fundamental Summary
The financials published by VistaGen Therapeutics for Q4 were weak and discouraging. Specifically, their growth and value factors indicate an execution challenge when it comes to generating exciting and consistent growth. These results indicate a weak growth potential for VistaGen Therapeutics's stock's price moving forward. As such, VistaGen Therapeutics received an overall score of 51 and a UNDERPERFORM recommendation.
VistaGen Therapeutics reported earnings results for the full year ended March 31, 2022. For the full year, the company reported revenue was USD 1.11 million compared to USD 1.09 million a year ago. Net loss was USD 47.76 million compared to USD 17.93 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.49 a year ago.
Business Description
VistaGen Therapeutics, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company’s CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics was founded in 1998 and is headquartered in South San Francisco, California.
Sector Overview
VistaGen Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. VistaGen Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -41.5 | 36.8% | 58 | |
| Net Cashflow | -20.6 | -126.4% | 70 | |
| Capital Expenditure | -0.2 | 40.1% | 95 | |
| Asset Turnover | 0.0 | -37.7% | 46 | |
| Free Cashflow | -0.2 | -3.8% | 64 |
* All values are TTM
The below chart reflects VistaGen Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While VistaGen Therapeutics's peer average final assessment score stands on 62.0, VistaGen Therapeutics's score is 51.
- VTGN
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. VistaGen Therapeutics's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), VistaGen Therapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 42.
5D MA
0.98
50D MA
1.15
200D MA
1.7
MACD
-0.05
RSI
3.78
STOCH
5.0
Balance Sheet Analysis
VistaGen Therapeutics's recently published balance sheet conveys disappointing growth, particularly with respect to Equity and Book Value Factors metrics. VistaGen Therapeutics reported weak equity changes momentum this period. At filing, equity was reported as 80.0, representing -0.8% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 7.7%. This performance is significantly less impressive than its peers and competitors. Consequently, their equity movement received a grade of 43. Also, VistaGen Therapeutics's price to book ratio (P/B) was reported as 5.0 and represents -24.5% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 23.0%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Consequently, their book value factors movement received a grade of 48. At the same time, one balance sheet metric, Assets, was actually strongly positive. The company's assets section could set high expectations for VistaGen Therapeutics's future attractiveness, as they went to 90.5, which is a -9.9% change from the last period. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Consequently, their asset movement received a grade of 71. The company's balance sheet, Therefore, earned a score of 52.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 90.5 | -9.9% | 71 |
| Liabilities | 10.6 | -17.7% | 50 |
| Price to Book | 5.0 | -24.5% | 48 |
| Cash & Equivalents | 83.7 | -10.6% | 55 |
| Equity | 80.0 | -0.8% | 43 |
The below chart describes VistaGen Therapeutics's performance as reflected on its balance sheet with respect to its peers. While VistaGen Therapeutics received a balance sheet score of 52, the average of its peers stands on 61.0.
- VTGN
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| StemCells Inc. | 187.3M | 64 | 65 | 49 | 41 | 95 | 60 | 0 | 1 |
| AquaBounty Technologies, Inc. | 123.0M | 45 | 68 | 60 | 60 | 71 | 68 | 1 | 1 |
| Anixa Biosciences, Inc. | 92.9M | 39 | 69 | 51 | 69 | 65 | 64 | 2 | 1 |
| GT Biopharma, Inc. | 90.3M | 54 | 67 | 89 | 57 | 47 | 75 | 3 | 1 |
| La Jolla Pharmaceutical Company | 84.8M | 61 | 68 | 92 | 71 | 57 | 81 | 4 | 1 |
| Athersys, Inc. | 67.6M | 73 | 64 | 42 | 44 | 37 | 50 | 5 | 1 |
| ImmuCell Corporation | 66.0M | 79 | 71 | 81 | 86 | 83 | 87 | 6 | 1 |
| Sunesis Pharmaceuticals, Inc. | 55.4M | 50 | 65 | 66 | 48 | 41 | 60 | 7 | 1 |
| Axonyx Inc. | 46.7M | 62 | 78 | 85 | 56 | 55 | 73 | 8 | 1 |
| CASI Pharmaceuticals, Inc. | 39.9M | 73 | 61 | 88 | 52 | 61 | 76 | 9 | 1 |
| Nymox Pharmaceutical Corporation | 39.7M | 93 | 67 | 60 | 57 | 37 | 63 | 10 | 1 |
| Caladrius Biosciences, Inc. | 31.8M | 38 | 70 | 90 | 41 | 67 | 80 | 11 | 1 |
| Zalicus Inc. | 30.8M | 81 | 67 | 78 | 43 | 42 | 65 | 12 | 1 |
| Aviragen Therapeutics, Inc. | 29.9M | 72 | 68 | 73 | 86 | 44 | 69 | 13 | 1 |
| AIkido Pharma Inc. | 29.5M | 45 | 68 | 76 | 53 | 66 | 74 | 14 | 1 |
| Abeona Therapeutics Inc. | 27.1M | 43 | 65 | 85 | 45 | 42 | 70 | 15 | 1 |
| Idera Pharmaceuticals, Inc. | 23.7M | 42 | 68 | 58 | 61 | 53 | 63 | 16 | 1 |
| Soligenix, Inc. | 23.3M | 80 | 69 | 52 | 63 | 41 | 60 | 17 | 1 |
| Critical Therapeutics, Inc. | 16.9M | 43 | 68 | 86 | 94 | 49 | 75 | 18 | 1 |
| Vical Incorporated | 15.4M | 37 | 71 | 63 | 67 | 62 | 68 | 19 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 14.7M | 87 | 65 | 62 | 57 | 59 | 67 | 20 | 1 |
| Celsion Corporation | 13.1M | 62 | 66 | 40 | 92 | 52 | 57 | 21 | 1 |
| Tenax Therapeutics, Inc. | 12.7M | 90 | 64 | 72 | 41 | 38 | 65 | 22 | 1 |
| Windtree Therapeutics, Inc. | 12.6M | 61 | 58 | 44 | 48 | 51 | 51 | 23 | 1 |
| Plus Therapeutics, Inc. | 11.5M | 47 | 69 | 65 | 86 | 67 | 72 | 24 | 1 |
| Telik Inc. | 6.4M | 56 | 73 | 56 | 58 | 49 | 60 | 25 | 1 |
| Lineage Cell Therapeutics, Inc. | 242.7M | 39 | 63 | 64 | 91 | 65 | 67 | 26 | 1 |
| XOMA Corporation | 231.0M | 40 | 66 | 53 | 71 | 70 | 65 | 27 | 1 |
| CEL-SCI Corporation | 192.8M | 79 | 66 | 56 | 69 | 56 | 64 | 28 | 1 |
| Spectrum Pharmaceuticals, Inc. | 149.3M | 40 | 69 | 55 | 64 | 91 | 71 | 29 | 1 |
| eXegenics Inc. | 129.4M | 83 | 66 | 42 | 73 | 59 | 53 | 30 | 1 |
| Gamida Cell Ltd. | 105.0M | 53 | 63 | 85 | 51 | 40 | 69 | 31 | 1 |
| Curis, Inc. | 92.6M | 47 | 86 | 74 | 40 | 53 | 80 | 32 | 1 |
| Trimeris Inc | 68.8M | 42 | 78 | 83 | 79 | 77 | 81 | 33 | 1 |
| Sensei Biotherapeutics, Inc. | 67.1M | 97 | 66 | 89 | 88 | 63 | 84 | 34 | 1 |
| Palatin Technologies, Inc. | 64.0M | 47 | 66 | 58 | 56 | 47 | 61 | 35 | 1 |
| iBio, Inc. | 61.4M | 68 | 67 | 59 | 61 | 55 | 65 | 36 | 1 |
| CancerVax Corp. | 60.7M | 66 | 72 | 77 | 54 | 41 | 53 | 37 | 1 |
| Protalix BioTherapeutics, Inc. | 50.4M | 60 | 68 | 46 | 40 | 46 | 56 | 38 | 1 |
| Nabi Biopharmaceuticals Inc. | 47.5M | 57 | 74 | 55 | 68 | 67 | 61 | 39 | 1 |
| AVANT Immunotherapeutics Inc. | 46.7M | 52 | 68 | 52 | 92 | 45 | 47 | 40 | 1 |
| Ainos, Inc. | 41.7M | 71 | 81 | 73 | 82 | 49 | 80 | 41 | 1 |
| AIM ImmunoTech Inc. | 40.8M | 78 | 77 | 58 | 66 | 64 | 74 | 42 | 1 |
| Oragenics, Inc. | 39.3M | 57 | 66 | 73 | 54 | 46 | 67 | 43 | 1 |
| Cell Genesys, Inc. | 35.9M | 48 | 70 | 45 | 39 | 97 | 71 | 44 | 1 |
| Targacept, Inc. | 32.9M | 69 | 70 | 55 | 76 | 69 | 67 | 45 | 1 |
| Inhibitor Therapeutics, Inc. | 30.1M | 76 | 67 | 78 | 58 | 71 | 78 | 46 | 1 |
| RegeneRx Biopharmaceuticals, Inc. | 25.8M | 66 | 65 | 74 | 51 | 51 | 69 | 47 | 1 |
| Enzon Pharmaceuticals, Inc. | 22.3M | 71 | 70 | 74 | 76 | 50 | 73 | 48 | 1 |
| Navidea Biopharmaceuticals, Inc. | 20.2M | 55 | 63 | 51 | 38 | 37 | 52 | 49 | 1 |
| HepaLife Technologies Inc. | 19.3M | 73 | 72 | 71 | 77 | 46 | 67 | 50 | 1 |
| AmpliPhi Biosciences Corporation | 13.4M | 88 | 67 | 46 | 47 | 40 | 52 | 51 | 1 |
| NovelStem International Corp. | 13.1M | 64 | 69 | 94 | 44 | 95 | 83 | 52 | 1 |
| Acorda Therapeutics, Inc. | 11.1M | 71 | 57 | 41 | 94 | 98 | 49 | 53 | 1 |
| Sonus Pharmaceuticals Inc. | 10.4M | 46 | 71 | 58 | 40 | 52 | 58 | 54 | 1 |
| Orthodontix Inc. | 9.7M | 62 | 76 | 76 | 61 | 54 | 74 | 55 | 1 |
| NeoPharm, Inc. | 7.4M | 74 | 67 | 54 | 72 | 77 | 64 | 56 | 1 |
| SyntheMed, Inc. | 7.0M | 71 | 69 | 48 | 67 | 50 | 65 | 57 | 1 |
| Nuvelo Inc. | 6.3M | 46 | 76 | 54 | 79 | 54 | 65 | 58 | 1 |
| Senetek plc | 6.1M | 48 | 67 | 79 | 61 | 79 | 83 | 59 | 1 |
| Manhattan Scientifics, Inc. | 5.9M | 78 | 73 | 74 | 53 | 38 | 69 | 60 | 1 |
| Dendreon Corporation | 5.0M | 70 | 68 | 49 | 71 | 68 | 59 | 61 | 1 |
| CytRx Corporation | 4.6M | 90 | 65 | 61 | 38 | 37 | 55 | 62 | 1 |
| U.S. Stem Cell, Inc. | 4.2M | 63 | 65 | 56 | 61 | 72 | 65 | 63 | 1 |
| TorreyPines Therapeutics, Inc. | 4.0M | 67 | 69 | 57 | 82 | 50 | 66 | 64 | 1 |
| Mateon Therapeutics, Inc. | 3.8M | 74 | 64 | 50 | 41 | 70 | 58 | 65 | 1 |
| Marina Biotech, Inc. | 3.0M | 49 | 57 | 57 | 43 | 93 | 61 | 66 | 1 |
| Capstone Therapeutics Corp. | 2.9M | 59 | 70 | 74 | 59 | 42 | 72 | 67 | 1 |
| Helix BioMedix, Inc. | 2.7M | 71 | 66 | 78 | 48 | 49 | 64 | 68 | 1 |
| Ceres Ventures, Inc. | 2.1M | 55 | 66 | 55 | 45 | 55 | 59 | 69 | 1 |
| Oscient Pharmaceuticals Corp. | 1.4M | 67 | 62 | 59 | 85 | 50 | 61 | 70 | 1 |
| Northfield Laboratories Inc. | 1.2M | 81 | 67 | 48 | 45 | 52 | 57 | 71 | 1 |
| W World Corp. | 881.2K | 47 | 73 | 54 | 67 | 85 | 73 | 72 | 1 |
| Genta Incorporated | 596.0K | 48 | 76 | 54 | 54 | 97 | 77 | 73 | 1 |
| Biopure Corporation | 476.5K | 46 | 68 | 42 | 42 | 52 | 50 | 74 | 1 |
| VG Life Sciences Inc. | 276.9K | 57 | 82 | 38 | 94 | 89 | 74 | 75 | 1 |
| Affymax, Inc. | 232.4K | 67 | 69 | 78 | 54 | 39 | 65 | 76 | 1 |
| Xechem International Inc. | 164.1K | 67 | 66 | 43 | 82 | 46 | 48 | 77 | 1 |
| Savient Pharmaceuticals, Inc. | 135.6K | 59 | 68 | 54 | 77 | 45 | 50 | 78 | 1 |
| Mera Pharmaceuticals, Inc. | 111.4K | 60 | 64 | 60 | 40 | 65 | 54 | 79 | 1 |
| Generex Biotechnology Corporation | 73.2K | 52 | 81 | 53 | 90 | 75 | 74 | 80 | 1 |
| AVAX Technologies, Inc. | 68.9K | 45 | 70 | 73 | 92 | 44 | 63 | 81 | 1 |
| Orchestra Therapeutics, Inc. | 58.1K | 57 | 69 | 46 | 40 | 48 | 49 | 82 | 1 |
| Protein Polymer Technologies Inc. | 56.5K | 69 | 96 | 52 | 83 | 44 | 77 | 83 | 1 |
| GlycoGenesys Inc. | 16.9K | 74 | 75 | 67 | 42 | 38 | 47 | 84 | 1 |
| NanoLogix, Inc. | 16.3K | 81 | 64 | 42 | 99 | 82 | 66 | 85 | 1 |
| Large Scale Biology Corp. | 12.9K | 64 | 40 | 97 | 97 | 50 | 63 | 86 | 1 |
| Bio Lab Naturals, Inc., Prior to Reverse Merger with BioProtein, Inc. | 10.3K | 60 | 78 | 41 | 62 | 38 | 40 | 87 | 1 |
| Panacos Pharmaceuticals, Inc. | 5.4K | 52 | 76 | 69 | 81 | 38 | 65 | 88 | 1 |
| MultiCell Technologies, Inc. | 5.0K | 75 | 68 | 44 | 98 | 42 | 57 | 89 | 1 |
| Introgen Therapeutics, Inc. | 4.4K | 61 | 75 | 49 | 92 | 37 | 58 | 90 | 1 |
| 9342-8530 Québec Inc. | 4.3K | 58 | 75 | 65 | 63 | 53 | 63 | 91 | 1 |
| Lipid Sciences, Inc. | 3.7K | 56 | 68 | 71 | 92 | 38 | 65 | 92 | 1 |
| Neurobiological Technologies, Inc. | 2.7K | 66 | 63 | 64 | 79 | 88 | 76 | 93 | 1 |
| BioSyntech, Inc. | 116.0 | 60 | 69 | 73 | 68 | 44 | 62 | 94 | 1 |
| Neurologix, Inc. | 27.0 | 74 | 70 | 64 | 43 | 62 | 67 | 95 | 1 |
| ReGen Biologics Inc. | 25.0 | 66 | 70 | 58 | 38 | 38 | 56 | 96 | 1 |
| Poniard Pharmaceuticals, Inc. | 1.0 | 67 | 68 | 54 | 45 | 54 | 57 | 97 | 1 |
Income Statement Analysis
A few key income statement metrics in this report were discouraging. VistaGen Therapeutics's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -36.4, which represents a -17.2% change from the last period. This metric might have a 23.8 percent impact on companies in the same industry and with the same market capitalization. VistaGen Therapeutics appears to be headed in the wrong direction in terms of EBITDA momentum, likely due to insufficient capital controls and a weaker than expected overall financial performance. Therefore, their EBITDA component earned a score of 50. Also, In this filing, VistaGen Therapeutics reported a return on equity (ROE) ratio of -41.5, which represents a growth of 36.8%. This metric might have a 2.9 percent impact on companies in the same industry and with the same market capitalization. They does not yet appear to be headed in the right direction regarding these return on equity and return on assets metrics. Consequently, their return factors received a grade of 58. However, one encouraging metric, Revenue Efficiency, stood out. VistaGen Therapeutics did an excellent job managing its revenue efficiency this past period. VistaGen Therapeutics's revenue efficiency is 1.5 according to the metrics in the current filing, which represents a 3.0% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 12.9%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. As a result, its revenue efficiency earned a score of 64. Because of these weaknesses, its income statement received an overall score of 55.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -36.4 | -17.2% | 50 |
| Total Revenues | 1.5 | 3.0% | 64 |
| Return on Equity | -41.5 | 36.8% | 58 |
The below chart describes VistaGen Therapeutics's performance as reflected on its income statement with respect to its peers. While VistaGen Therapeutics received a income statement score of 55 , the average of its peers stands on 68.0.
- VTGN
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| StemCells Inc. | 187.3M | 49 | 91 | 78 | 88 | 0 | 1 |
| AquaBounty Technologies, Inc. | 123.0M | 96 | 64 | 88 | 68 | 1 | 1 |
| Anixa Biosciences, Inc. | 92.9M | 59 | 55 | 89 | 57 | 2 | 1 |
| GT Biopharma, Inc. | 90.3M | 59 | 79 | 66 | 78 | 3 | 1 |
| La Jolla Pharmaceutical Company | 84.8M | 38 | 38 | 68 | 40 | 4 | 1 |
| Athersys, Inc. | 67.6M | 96 | 80 | 63 | 81 | 5 | 1 |
| ImmuCell Corporation | 66.0M | 85 | 97 | 99 | 97 | 6 | 1 |
| Sunesis Pharmaceuticals, Inc. | 55.4M | 37 | 74 | 57 | 70 | 7 | 1 |
| Axonyx Inc. | 46.7M | 74 | 91 | 78 | 91 | 8 | 1 |
| CASI Pharmaceuticals, Inc. | 39.9M | 87 | 86 | 84 | 87 | 9 | 1 |
| Nymox Pharmaceutical Corporation | 39.7M | 59 | 45 | 68 | 47 | 10 | 1 |
| Caladrius Biosciences, Inc. | 31.8M | 59 | 85 | 94 | 84 | 11 | 1 |
| Zalicus Inc. | 30.8M | 41 | 84 | 44 | 76 | 12 | 1 |
| Aviragen Therapeutics, Inc. | 29.9M | 42 | 93 | 76 | 87 | 13 | 1 |
| AIkido Pharma Inc. | 29.5M | 59 | 62 | 93 | 64 | 14 | 1 |
| Abeona Therapeutics Inc. | 27.1M | 87 | 68 | 49 | 69 | 15 | 1 |
| Idera Pharmaceuticals, Inc. | 23.7M | 59 | 87 | 93 | 86 | 16 | 1 |
| Soligenix, Inc. | 23.3M | 79 | 53 | 82 | 57 | 17 | 1 |
| Critical Therapeutics, Inc. | 16.9M | 63 | 89 | 68 | 86 | 18 | 1 |
| Vical Incorporated | 15.4M | 37 | 86 | 81 | 80 | 19 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 14.7M | 59 | 59 | 79 | 60 | 20 | 1 |
| Celsion Corporation | 13.1M | 59 | 66 | 83 | 67 | 21 | 1 |
| Tenax Therapeutics, Inc. | 12.7M | 59 | 97 | 93 | 95 | 22 | 1 |
| Windtree Therapeutics, Inc. | 12.6M | 59 | 81 | 82 | 80 | 23 | 1 |
| Plus Therapeutics, Inc. | 11.5M | 59 | 63 | 87 | 64 | 24 | 1 |
| Telik Inc. | 6.4M | 76 | 80 | 63 | 78 | 25 | 1 |
| Lineage Cell Therapeutics, Inc. | 242.7M | 97 | 72 | 70 | 74 | 26 | 1 |
| XOMA Corporation | 231.0M | 82 | 94 | 92 | 94 | 27 | 1 |
| CEL-SCI Corporation | 192.8M | 59 | 68 | 60 | 67 | 28 | 1 |
| Spectrum Pharmaceuticals, Inc. | 149.3M | 59 | 88 | 79 | 87 | 29 | 1 |
| eXegenics Inc. | 129.4M | 75 | 52 | 62 | 56 | 30 | 1 |
| Gamida Cell Ltd. | 105.0M | 59 | 70 | 59 | 70 | 31 | 1 |
| Curis, Inc. | 92.6M | 48 | 47 | 47 | 47 | 32 | 1 |
| Trimeris Inc | 68.8M | 67 | 54 | 65 | 57 | 33 | 1 |
| Sensei Biotherapeutics, Inc. | 67.1M | 59 | 65 | 93 | 66 | 34 | 1 |
| Palatin Technologies, Inc. | 64.0M | 90 | 60 | 51 | 62 | 35 | 1 |
| iBio, Inc. | 61.4M | 96 | 48 | 49 | 52 | 36 | 1 |
| CancerVax Corp. | 60.7M | 68 | 83 | 96 | 82 | 37 | 1 |
| Protalix BioTherapeutics, Inc. | 50.4M | 87 | 86 | 62 | 86 | 38 | 1 |
| Nabi Biopharmaceuticals Inc. | 47.5M | 37 | 88 | 78 | 86 | 39 | 1 |
| AVANT Immunotherapeutics Inc. | 46.7M | 94 | 67 | 51 | 67 | 40 | 1 |
| Ainos, Inc. | 41.7M | 89 | 51 | 40 | 53 | 41 | 1 |
| AIM ImmunoTech Inc. | 40.8M | 76 | 71 | 78 | 72 | 42 | 1 |
| Oragenics, Inc. | 39.3M | 90 | 66 | 87 | 69 | 43 | 1 |
| Cell Genesys, Inc. | 35.9M | 95 | 83 | 76 | 83 | 44 | 1 |
| Targacept, Inc. | 32.9M | 39 | 89 | 87 | 89 | 45 | 1 |
| Inhibitor Therapeutics, Inc. | 30.1M | 59 | 72 | 71 | 72 | 46 | 1 |
| RegeneRx Biopharmaceuticals, Inc. | 25.8M | 59 | 61 | 50 | 61 | 47 | 1 |
| Enzon Pharmaceuticals, Inc. | 22.3M | 37 | 64 | 40 | 62 | 48 | 1 |
| Navidea Biopharmaceuticals, Inc. | 20.2M | 39 | 74 | 72 | 72 | 49 | 1 |
| HepaLife Technologies Inc. | 19.3M | 77 | 79 | 78 | 81 | 50 | 1 |
| AmpliPhi Biosciences Corporation | 13.4M | 59 | 67 | 64 | 67 | 51 | 1 |
| NovelStem International Corp. | 13.1M | 98 | 68 | 81 | 75 | 52 | 1 |
| Acorda Therapeutics, Inc. | 11.1M | 45 | 94 | 80 | 88 | 53 | 1 |
| Sonus Pharmaceuticals Inc. | 10.4M | 97 | 81 | 55 | 81 | 54 | 1 |
| Orthodontix Inc. | 9.7M | 74 | 55 | 58 | 58 | 55 | 1 |
| NeoPharm, Inc. | 7.4M | 72 | 55 | 58 | 57 | 56 | 1 |
| SyntheMed, Inc. | 7.0M | 44 | 68 | 65 | 66 | 57 | 1 |
| Nuvelo Inc. | 6.3M | 79 | 88 | 74 | 88 | 58 | 1 |
| Senetek plc | 6.1M | 45 | 65 | 59 | 63 | 59 | 1 |
| Manhattan Scientifics, Inc. | 5.9M | 60 | 65 | 82 | 66 | 60 | 1 |
| Dendreon Corporation | 5.0M | 95 | 68 | 76 | 71 | 61 | 1 |
| CytRx Corporation | 4.6M | 59 | 54 | 38 | 54 | 62 | 1 |
| U.S. Stem Cell, Inc. | 4.2M | 53 | 94 | 71 | 87 | 63 | 1 |
| TorreyPines Therapeutics, Inc. | 4.0M | 95 | 59 | 48 | 60 | 64 | 1 |
| Mateon Therapeutics, Inc. | 3.8M | 61 | 67 | 70 | 67 | 65 | 1 |
| Marina Biotech, Inc. | 3.0M | 96 | 53 | 52 | 54 | 66 | 1 |
| Capstone Therapeutics Corp. | 2.9M | 61 | 52 | 46 | 52 | 67 | 1 |
| Helix BioMedix, Inc. | 2.7M | 90 | 82 | 77 | 84 | 68 | 1 |
| Ceres Ventures, Inc. | 2.1M | 76 | 83 | 63 | 79 | 69 | 1 |
| Oscient Pharmaceuticals Corp. | 1.4M | 55 | 57 | 79 | 61 | 70 | 1 |
| Northfield Laboratories Inc. | 1.2M | 76 | 53 | 58 | 53 | 71 | 1 |
| W World Corp. | 881.2K | 74 | 82 | 51 | 69 | 72 | 1 |
| Genta Incorporated | 596.0K | 57 | 81 | 68 | 81 | 73 | 1 |
| Biopure Corporation | 476.5K | 62 | 87 | 61 | 77 | 74 | 1 |
| VG Life Sciences Inc. | 276.9K | 59 | 69 | 71 | 71 | 75 | 1 |
| Affymax, Inc. | 232.4K | 37 | 96 | 49 | 87 | 76 | 1 |
| Xechem International Inc. | 164.1K | 38 | 59 | 43 | 53 | 77 | 1 |
| Savient Pharmaceuticals, Inc. | 135.6K | 90 | 71 | 89 | 75 | 78 | 1 |
| Mera Pharmaceuticals, Inc. | 111.4K | 88 | 96 | 78 | 99 | 79 | 1 |
| Generex Biotechnology Corporation | 73.2K | 37 | 68 | 55 | 64 | 80 | 1 |
| AVAX Technologies, Inc. | 68.9K | 91 | 60 | 38 | 60 | 81 | 1 |
| Orchestra Therapeutics, Inc. | 58.1K | 37 | 69 | 43 | 61 | 82 | 1 |
| Protein Polymer Technologies Inc. | 56.5K | 94 | 82 | 39 | 79 | 83 | 1 |
| GlycoGenesys Inc. | 16.9K | 77 | 82 | 81 | 87 | 84 | 1 |
| NanoLogix, Inc. | 16.3K | 97 | 84 | 94 | 91 | 85 | 1 |
| Large Scale Biology Corp. | 12.9K | 94 | 73 | 52 | 72 | 86 | 1 |
| Bio Lab Naturals, Inc., Prior to Reverse Merger with BioProtein, Inc. | 10.3K | 76 | 53 | 73 | 60 | 87 | 1 |
| Panacos Pharmaceuticals, Inc. | 5.4K | 92 | 66 | 53 | 67 | 88 | 1 |
| MultiCell Technologies, Inc. | 5.0K | 89 | 51 | 60 | 57 | 89 | 1 |
| Introgen Therapeutics, Inc. | 4.4K | 41 | 80 | 51 | 73 | 90 | 1 |
| 9342-8530 Québec Inc. | 4.3K | 41 | 59 | 58 | 59 | 91 | 1 |
| Lipid Sciences, Inc. | 3.7K | 97 | 78 | 47 | 76 | 92 | 1 |
| Neurobiological Technologies, Inc. | 2.7K | 46 | 99 | 71 | 90 | 93 | 1 |
| BioSyntech, Inc. | 116.0 | 41 | 70 | 46 | 64 | 94 | 1 |
| Neurologix, Inc. | 27.0 | 75 | 76 | 39 | 71 | 95 | 1 |
| ReGen Biologics Inc. | 25.0 | 44 | 52 | 59 | 49 | 96 | 1 |
| Poniard Pharmaceuticals, Inc. | 1.0 | 75 | 88 | 67 | 88 | 97 | 1 |
Cash Flow Analysis
Capex and Net Cash Flow stand out as the most significant drivers of VistaGen Therapeutics's cash flow's strength. VistaGen Therapeutics's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -0.2, which represents a 40.1% change from the last period. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Therefore, its CapEx movement component earned a score of 95. Also, VistaGen Therapeutics's strong net cash flow numbers, which were -20.6 in this filing, showed a -126.4% change from the last period. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. The company's net cash flow, therefore, received a grade of 70. However, one discouraging result, Asset Turnover, stood out. Asset turnover metrics during this period were surprisingly weak. Their reported asset turnover metrics of 0.0, which represents a -37.7% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 3.2 percent by this parameter. Their lackluster asset turnover metrics, specifically in contrast to leading industry peers' performance, could present significant headwinds. Correspondingly, their asset turnover movement received a grade of 46. Consequently, its cash flow earned a score of 70.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -20.6 | -126.4% | 70 |
| Capital Expenditure | -0.2 | 40.1% | 95 |
| Asset Turnover | 0.0 | -37.7% | 46 |
| Free Cashflow | -0.2 | -3.8% | 64 |
The below chart describes VistaGen Therapeutics's performance as reflected on its cash flow with respect to its peers. While VistaGen Therapeutics received a cash flow score of 70, the average of its peers stands on 68.0.
- VTGN
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| StemCells Inc. | 187.3M | 74 | 58 | 96 | 93 | 89 | 0 | 1 |
| AquaBounty Technologies, Inc. | 123.0M | 68 | 89 | 40 | 42 | 71 | 1 | 1 |
| Anixa Biosciences, Inc. | 92.9M | 60 | 89 | 67 | 41 | 68 | 2 | 1 |
| GT Biopharma, Inc. | 90.3M | 63 | 63 | 67 | 75 | 71 | 3 | 1 |
| La Jolla Pharmaceutical Company | 84.8M | 57 | 94 | 67 | 58 | 74 | 4 | 1 |
| Athersys, Inc. | 67.6M | 67 | 74 | 54 | 92 | 82 | 5 | 1 |
| ImmuCell Corporation | 66.0M | 80 | 41 | 49 | 45 | 64 | 6 | 1 |
| Sunesis Pharmaceuticals, Inc. | 55.4M | 61 | 69 | 65 | 75 | 67 | 7 | 1 |
| Axonyx Inc. | 46.7M | 71 | 82 | 76 | 68 | 75 | 8 | 1 |
| CASI Pharmaceuticals, Inc. | 39.9M | 86 | 48 | 50 | 85 | 83 | 9 | 1 |
| Nymox Pharmaceutical Corporation | 39.7M | 52 | 86 | 91 | 94 | 81 | 10 | 1 |
| Caladrius Biosciences, Inc. | 31.8M | 83 | 50 | 67 | 40 | 70 | 11 | 1 |
| Zalicus Inc. | 30.8M | 84 | 46 | 81 | 47 | 67 | 12 | 1 |
| Aviragen Therapeutics, Inc. | 29.9M | 72 | 50 | 67 | 75 | 75 | 13 | 1 |
| AIkido Pharma Inc. | 29.5M | 57 | 90 | 67 | 43 | 67 | 14 | 1 |
| Abeona Therapeutics Inc. | 27.1M | 70 | 54 | 81 | 69 | 73 | 15 | 1 |
| Idera Pharmaceuticals, Inc. | 23.7M | 84 | 46 | 67 | 50 | 72 | 16 | 1 |
| Soligenix, Inc. | 23.3M | 80 | 56 | 40 | 87 | 81 | 17 | 1 |
| Critical Therapeutics, Inc. | 16.9M | 65 | 48 | 46 | 52 | 51 | 18 | 1 |
| Vical Incorporated | 15.4M | 55 | 77 | 89 | 39 | 54 | 19 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 14.7M | 59 | 82 | 98 | 88 | 83 | 20 | 1 |
| Celsion Corporation | 13.1M | 59 | 75 | 88 | 81 | 77 | 21 | 1 |
| Tenax Therapeutics, Inc. | 12.7M | 74 | 53 | 39 | 96 | 78 | 22 | 1 |
| Windtree Therapeutics, Inc. | 12.6M | 69 | 59 | 57 | 89 | 77 | 23 | 1 |
| Plus Therapeutics, Inc. | 11.5M | 62 | 54 | 38 | 42 | 54 | 24 | 1 |
| Telik Inc. | 6.4M | 82 | 71 | 84 | 52 | 67 | 25 | 1 |
| Lineage Cell Therapeutics, Inc. | 242.7M | 91 | 38 | 52 | 41 | 70 | 26 | 1 |
| XOMA Corporation | 231.0M | 65 | 38 | 67 | 40 | 53 | 27 | 1 |
| CEL-SCI Corporation | 192.8M | 83 | 48 | 94 | 92 | 89 | 28 | 1 |
| Spectrum Pharmaceuticals, Inc. | 149.3M | 73 | 59 | 84 | 45 | 70 | 29 | 1 |
| eXegenics Inc. | 129.4M | 60 | 95 | 66 | 88 | 79 | 30 | 1 |
| Gamida Cell Ltd. | 105.0M | 69 | 77 | 84 | 74 | 83 | 31 | 1 |
| Curis, Inc. | 92.6M | 62 | 84 | 94 | 41 | 71 | 32 | 1 |
| Trimeris Inc | 68.8M | 70 | 98 | 66 | 93 | 83 | 33 | 1 |
| Sensei Biotherapeutics, Inc. | 67.1M | 76 | 55 | 90 | 94 | 86 | 34 | 1 |
| Palatin Technologies, Inc. | 64.0M | 58 | 90 | 43 | 70 | 73 | 35 | 1 |
| iBio, Inc. | 61.4M | 86 | 66 | 79 | 76 | 90 | 36 | 1 |
| CancerVax Corp. | 60.7M | 91 | 87 | 89 | 80 | 91 | 37 | 1 |
| Protalix BioTherapeutics, Inc. | 50.4M | 90 | 42 | 81 | 81 | 86 | 38 | 1 |
| Nabi Biopharmaceuticals Inc. | 47.5M | 72 | 47 | 40 | 84 | 74 | 39 | 1 |
| AVANT Immunotherapeutics Inc. | 46.7M | 67 | 71 | 67 | 95 | 85 | 40 | 1 |
| Ainos, Inc. | 41.7M | 43 | 94 | 40 | 37 | 54 | 41 | 1 |
| AIM ImmunoTech Inc. | 40.8M | 79 | 61 | 67 | 79 | 83 | 42 | 1 |
| Oragenics, Inc. | 39.3M | 66 | 81 | 38 | 86 | 79 | 43 | 1 |
| Cell Genesys, Inc. | 35.9M | 98 | 40 | 96 | 63 | 79 | 44 | 1 |
| Targacept, Inc. | 32.9M | 75 | 53 | 57 | 39 | 56 | 45 | 1 |
| Inhibitor Therapeutics, Inc. | 30.1M | 82 | 57 | 67 | 91 | 88 | 46 | 1 |
| RegeneRx Biopharmaceuticals, Inc. | 25.8M | 62 | 79 | 67 | 85 | 80 | 47 | 1 |
| Enzon Pharmaceuticals, Inc. | 22.3M | 46 | 94 | 67 | 67 | 69 | 48 | 1 |
| Navidea Biopharmaceuticals, Inc. | 20.2M | 78 | 60 | 38 | 97 | 84 | 49 | 1 |
| HepaLife Technologies Inc. | 19.3M | 72 | 73 | 69 | 86 | 79 | 50 | 1 |
| AmpliPhi Biosciences Corporation | 13.4M | 83 | 48 | 50 | 85 | 81 | 51 | 1 |
| NovelStem International Corp. | 13.1M | 70 | 72 | 68 | 39 | 51 | 52 | 1 |
| Acorda Therapeutics, Inc. | 11.1M | 68 | 71 | 68 | 78 | 74 | 53 | 1 |
| Sonus Pharmaceuticals Inc. | 10.4M | 72 | 84 | 74 | 43 | 59 | 54 | 1 |
| Orthodontix Inc. | 9.7M | 75 | 41 | 69 | 65 | 70 | 55 | 1 |
| NeoPharm, Inc. | 7.4M | 64 | 71 | 64 | 77 | 70 | 56 | 1 |
| SyntheMed, Inc. | 7.0M | 55 | 64 | 66 | 89 | 75 | 57 | 1 |
| Nuvelo Inc. | 6.3M | 50 | 50 | 89 | 76 | 69 | 58 | 1 |
| Senetek plc | 6.1M | 76 | 89 | 65 | 56 | 69 | 59 | 1 |
| Manhattan Scientifics, Inc. | 5.9M | 66 | 74 | 80 | 82 | 76 | 60 | 1 |
| Dendreon Corporation | 5.0M | 65 | 66 | 77 | 70 | 72 | 61 | 1 |
| CytRx Corporation | 4.6M | 50 | 96 | 66 | 97 | 80 | 62 | 1 |
| U.S. Stem Cell, Inc. | 4.2M | 52 | 89 | 97 | 63 | 69 | 63 | 1 |
| TorreyPines Therapeutics, Inc. | 4.0M | 63 | 59 | 74 | 55 | 59 | 64 | 1 |
| Mateon Therapeutics, Inc. | 3.8M | 76 | 59 | 67 | 90 | 87 | 65 | 1 |
| Marina Biotech, Inc. | 3.0M | 76 | 51 | 68 | 96 | 87 | 66 | 1 |
| Capstone Therapeutics Corp. | 2.9M | 63 | 80 | 69 | 95 | 85 | 67 | 1 |
| Helix BioMedix, Inc. | 2.7M | 71 | 80 | 95 | 89 | 89 | 68 | 1 |
| Ceres Ventures, Inc. | 2.1M | 73 | 79 | 63 | 90 | 87 | 69 | 1 |
| Oscient Pharmaceuticals Corp. | 1.4M | 81 | 58 | 54 | 84 | 78 | 70 | 1 |
| Northfield Laboratories Inc. | 1.2M | 67 | 51 | 40 | 92 | 68 | 71 | 1 |
| W World Corp. | 881.2K | 69 | 82 | 40 | 50 | 58 | 72 | 1 |
| Genta Incorporated | 596.0K | 78 | 91 | 57 | 88 | 82 | 73 | 1 |
| Biopure Corporation | 476.5K | 81 | 77 | 98 | 95 | 95 | 74 | 1 |
| VG Life Sciences Inc. | 276.9K | 74 | 77 | 67 | 41 | 59 | 75 | 1 |
| Affymax, Inc. | 232.4K | 77 | 46 | 69 | 85 | 81 | 76 | 1 |
| Xechem International Inc. | 164.1K | 63 | 54 | 75 | 83 | 77 | 77 | 1 |
| Savient Pharmaceuticals, Inc. | 135.6K | 86 | 54 | 83 | 92 | 93 | 78 | 1 |
| Mera Pharmaceuticals, Inc. | 111.4K | 42 | 89 | 97 | 63 | 66 | 79 | 1 |
| Generex Biotechnology Corporation | 73.2K | 91 | 43 | 66 | 51 | 74 | 80 | 1 |
| AVAX Technologies, Inc. | 68.9K | 72 | 48 | 76 | 91 | 81 | 81 | 1 |
| Orchestra Therapeutics, Inc. | 58.1K | 84 | 91 | 85 | 93 | 94 | 82 | 1 |
| Protein Polymer Technologies Inc. | 56.5K | 51 | 76 | 95 | 65 | 67 | 83 | 1 |
| GlycoGenesys Inc. | 16.9K | 93 | 82 | 94 | 89 | 99 | 84 | 1 |
| NanoLogix, Inc. | 16.3K | 77 | 42 | 98 | 83 | 83 | 85 | 1 |
| Large Scale Biology Corp. | 12.9K | 69 | 69 | 68 | 99 | 79 | 86 | 1 |
| Bio Lab Naturals, Inc., Prior to Reverse Merger with BioProtein, Inc. | 10.3K | 70 | 77 | 69 | 80 | 84 | 87 | 1 |
| Panacos Pharmaceuticals, Inc. | 5.4K | 77 | 61 | 66 | 89 | 86 | 88 | 1 |
| MultiCell Technologies, Inc. | 5.0K | 42 | 58 | 94 | 39 | 46 | 89 | 1 |
| Introgen Therapeutics, Inc. | 4.4K | 64 | 77 | 55 | 95 | 85 | 90 | 1 |
| 9342-8530 Québec Inc. | 4.3K | 61 | 84 | 56 | 65 | 64 | 91 | 1 |
| Lipid Sciences, Inc. | 3.7K | 79 | 73 | 87 | 85 | 87 | 92 | 1 |
| Neurobiological Technologies, Inc. | 2.7K | 74 | 85 | 98 | 49 | 76 | 93 | 1 |
| BioSyntech, Inc. | 116.0 | 61 | 59 | 90 | 95 | 84 | 94 | 1 |
| Neurologix, Inc. | 27.0 | 71 | 72 | 66 | 88 | 79 | 95 | 1 |
| ReGen Biologics Inc. | 25.0 | 63 | 52 | 72 | 97 | 81 | 96 | 1 |
| Poniard Pharmaceuticals, Inc. | 1.0 | 68 | 89 | 66 | 97 | 84 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.